CN100435810C - Dogwood fruit extract and its preparation process - Google Patents
Dogwood fruit extract and its preparation process Download PDFInfo
- Publication number
- CN100435810C CN100435810C CNB2005100414807A CN200510041480A CN100435810C CN 100435810 C CN100435810 C CN 100435810C CN B2005100414807 A CNB2005100414807 A CN B2005100414807A CN 200510041480 A CN200510041480 A CN 200510041480A CN 100435810 C CN100435810 C CN 100435810C
- Authority
- CN
- China
- Prior art keywords
- extract
- fructus corni
- ethanol
- acid
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a dogwood extract product and a preparation process thereof, which has the technical scheme that the proportion of oleanolic acid, ursolic acid, loganin and morroniside is 1 to 5 /6 to 12/ 12 to 20 / 25. The preparing process comprises the steps that the dogwood is extracted by alcohol, the extracted liquid is kept at low temperature after concentrated, the upper solid is processed by acid and alkali, and an extract product (A) is obtained; the lower clear liquid is separated by macroporous resin columns, and an extract product (B) is obtained; the dogwood extract product is obtained by mixing the extract product (A) and the extract product (B). The present invention can be used for treating diabetes and complicating diseases thereof.
Description
Technical field
The present invention relates to a kind of Fructus Corni extract, also relate to this preparation method of extract and purposes, belong to the field of Chinese medicines.
Background technology
It is the endocrine-metabolic disease of feature with the hyperglycemia that diabetes are one group, in recent years become a kind of frequently-occurring disease, no matter in developed country or developing country, all become the third-largest serious Chronic Non-Communicable Diseases after tumor, angiopathy or, classified as one of the world's three big pertinacious diseases by WHO.Still the medicine that lacks radical cure at present, treatment is many based on Western medicine clinically, but has side effect such as hypoglycemia, gastrointestinal reaction, liver toxicity.Along with the prolongation of treatment time, hypoglycemic effect is reduction trend.Therefore, Chinese medicine is little with its toxic and side effects, action temperature and lasting, have the Comprehensive Treatment effect, can delay advantage such as complication, become an important channel seeking the blood sugar lowering new drug.
Be main effectively medical material since Japanese scholar in 1981 filters out Fructus Corni (Fructus Corni) from the compound recipe " eight flavor balls " with lowering blood sugar and preventing thirst effect, oleanolic acid wherein and ursolic acid are (YAKUGAKU ZASSHI, 1981 behind the main effective ingredient; 101 (1): 86-90), to the chemical constituent of Fructus Corni blood sugar reducing function and pharmacology activity research just day by day hot topic get up.The upright recklessly extensive scholar of The National Center for Drug Screening of Shanghai medicine institute of the Chinese Academy of Sciences found protein-tyrosine-phosphatase 1B inhibitor from Fructus Corni Cornus officinalis Sieb.et Zucc. in 2002, the active component parent is oleanolic acid and ursolic acid, is used for the treatment of diabetes, obesity and complication thereof.Chengdu buchu in 2004 filters out Fructus Corni and has good alpha-glucosidase inhibitor effect, number of patent application 03135217.0 from plurality of Chinese.Iridoid glycoside treatment diabetic angiopathy Study on mechanism in the Fructus Corni has been studied by Jiangsu Zhongkang New Drug ﹠ Fingerprinting R﹠D Inc., number of patent application 200410014770.8, and the extraction process 200410014769.5 of iridoid glycoside and total triterpene acid is disclosed.
Though research work is a lot, but the composition of blood sugar lowering effective ingredient has very big influence to its hypoglycemic effect in the Fructus Corni, list all can not play tangible blood sugar reducing function with total triterpene acid (oleanolic acid and ursolic acid) or iridoid glycoside (meliatin and morroniside), and iridoid glycoside uses excessive meeting to cause side effect.Iridoid glycoside and triterpenic acid are the negative and positive the two poles of the earth in the Fructus Corni, must be in harmonious proportion mutually, complement each other.Because triterpenic acid content is low in the Fructus Corni, also there is not the high-load triterpenic acid of the real effectively preparation of a kind of technology.The composition of effective ingredient and ratio do not have concrete report yet.
Summary of the invention
The purpose of this invention is to provide a kind of Fructus Corni extract newly forms.
Another object of the present invention provides a kind of preparation technology of Fructus Corni extract.
A further object of the invention provides a kind of new purposes of Fructus Corni extract, i.e. new application in pharmacy.
Technical problem that the present invention solves and the technical scheme that is adopted are as follows:
A kind of Fructus Corni extract, the content that it is characterized in that main active in the extract is 40%～80%, wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=(1～5): (6～12): (12～20): 25.
A kind of Fructus Corni extract preparation technology is characterized in that comprising following steps:
(1) Fructus Corni medical material ethanol extraction, filtering and concentrating is to there not being the alcohol flavor;
(2) the concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid;
(3) solid ethanol heating for dissolving is filtered, and filtrate adds aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and the solid ethyl alcohol recrystallization gets extract A;
(4) macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used ethanol gradient elution, collect eluent, are concentrated into dried extractum;
(5) extractum dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B;
Extract A and B uniform mixing are got Fructus Corni extract.
The condition and range of said extracted method is: extracting method is that alcohol heating reflux extracts in the step (1), and concentration of alcohol is 70～95%, and the volume multiple is 6～12, and extraction time is 1～2 hour, and extraction time is 2～3 times.Concentration of alcohol is 80～100% in the step (3); Aqueous slkali is sodium hydroxide or hydroxide sodium potassium, and concentration is greater than 10%; Acid solution is a dilute hydrochloric acid, and concentration is less than 10%.Concentration of alcohol is 40～80% in the step (4).Concentration of alcohol is 95～100% in the step (5).Middle extract A of step (6) and B be 1: 2～5 ratio uniform mixing by weight.
A contains 35～55% ursolic acids in the Fructus Corni extract of the present invention, 8～20% oleanolic acid.Extract B contains 25～40% morronisides, 15～25% meliatins.The content that mixes main active in the total extract of back is 40%～80%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=(1～5): (6～12): (12～20): 25.
The said Fructus Corni medical material of the present invention is a Cornaceae plant Fructus Corni Cornus officinalis Sieb.et Zucc. pulp.
The present invention carries out the qualitative and high performance liquid chromatogram standard measure of development process to Fructus Corni extract.
(1) the qualitative condition of development process of the present invention is as follows:
Oleanolic acid and ursolic acid: the vanillin strong sulfuric acid response positive (purplish red), alphanaphthol reaction feminine gender
Meliatin: aniline hydrochloride reacting positive (bright cherry-red), the alphanaphthol reaction positive (purplish red colour circle), the vanillin strong sulfuric acid response positive (purplish red)
Morroniside: aniline hydrochloride reacting positive (bright cherry-red), the alphanaphthol reaction positive (purplish red colour circle), the vanillin strong sulfuric acid response positive (pink)
(2) high-efficient liquid phase technique quantitative conditions of the present invention is as follows:
The chromatographic condition of a extract A:
Chromatographic column: Kromasil C
18(200 * 4.60mm, 5 μ); Mobile phase: acetonitrile-water-methanol-ethanol ammonium (80: 10: 10: 0.5); Flow velocity: 1ml/min; Detect wavelength: 215nm.
By analysis, A contains 35～55% ursolic acids in the extract, 8～20% oleanolic acid.Contain 1～10% oleanolic acid in the mixed extract, 5～20% ursolic acids.
The chromatographic condition of b extract B:
Chromatographic column: Kromasil C
18(200 * 4.60mm, 5 μ); Mobile phase: water-methanol (70: 30); Flow velocity: 1ml/min; Detect wavelength: 240nm.
8. by analysis, extract B contains
25～40% morronisides, 15～25% meliatins.Contain 10～25% meliatins in the mixed extract, 15～25% morronisides.
Fructus Corni extract of the present invention can be used as the application in the medicine of preparation treatment diabetes and complication thereof.
Beneficial effect of the present invention is as follows:
1, extraction process safety economy of the present invention has improved content of effective, reaches pharmaceutical standards fully.Especially the innovation of the preparation separating technology of oleanolic acid and ursolic acid in Fructus Corni, the oleanolic acid and the ursolic acid that have only 0.3～0.8% in the medical material are purified to more than 50%, do not reach in this former Fructus Corni extract, do not have any purifying process report yet.This technology has also been optimized the preparation technology of meliatin and morroniside, further removes water-solubility impurity wherein, has guaranteed the stability of product quality, and this does not have report yet in forefathers' research.
2, the clear and definite first effective ingredient of the present invention is formed, innovation proportioning, rational Application.As effective ingredient in Chinese, contain more than a kind of chemical constituent, having only a few composition is to have tangible curative effect, reasonably just has drug synergism under the composition situation, otherwise is then affecting the treatment.Iridoid glycoside and triterpenic acid are the negative and positive the two poles of the earth in the Fructus Corni, must be in harmonious proportion mutually, complement each other.The best effective ingredient weight ratio of research is an oleanolic acid: ursolic acid: meliatin: morroniside=(1～5): (6～12): (12～20): 25, this is to have illustrated the proportioning of sugar-lowering components in the Fructus Corni first, and spelling out these 4 kinds of chemical compounds is effective ingredient.
3, effective dose of the present invention is little, can obviously reduce the blood glucose value of diabetic mice and rat, is a kind of natural antidiabetic drug efficiently.The I of effective using dosage of the present invention reaches 30mg/kg, in the streptozotocin rat model, be better than BAITANGPING 20mg/kg, obviously be better than the Fructus Corni extract effective dose (greater than 100mg/kg) of report in the past, also obviously be better than the effective dose (greater than 500mg/kg) of existing blood-sugar lowering tcm drug.
Experimental example 1 Fructus Corni extract is to the influence of alloxan diabetes model mice blood glucose
Experiment purpose: observe the therapeutical effect of the present invention to alloxan diabetes model mice hyperglycemia.
Experimental technique: get male mice, behind fasting (the can't help water) 12h, the alloxan physiological salt liquid of the new preparation of tail vein injection 80mg/kg, behind the 72h, afterbody is got blood and is surveyed blood glucose value.Select 70 of the mices of blood glucose＞11.1mmol/L, be divided into 5 groups at random, be i.e. negative control group, model group, BAITANGPING group 30mg/kg, Fructus Corni extract low dose group 25mg/kg, middle dosage group 50mg/kg, high dose group 100mg/kg.After the administration, each irritates stomach starch 5g/kg, surveys blood glucose value after 0,1,2,4,6 hour.
The influence (n=14) of table 1 pair alloxan diabetes model mice blood glucose
Compare with model group,
*P＜0.05,
*P＜0.01
Experimental result: rat blood sugar obviously raises after the modeling.After giving Fructus Corni extract and BAITANGPING, blood glucose value obviously reduces.The Fructus Corni extract hypoglycemic effect is lower than BAITANGPING slightly.
Experimental example 2 Fructus Corni extracts are to the influence of streptozotocin rat model blood glucose
Experiment purpose: observe the therapeutical effect of the present invention to streptozotocin rat model hyperglycemia.
Experimental technique: get normal rat, behind fasting (the can't help water) 24h, the streptozotocin of the new preparation of tail vein injection 60mg/kg, after 1 week, afterbody is got blood and is surveyed blood glucose value.Select 40 of the mices of blood glucose＞16.7mmol/L, be divided into 5 groups at random, be i.e. negative control group, model group, BAITANGPING group 20mg/kg, Fructus Corni extract low dose group 15mg/kg, middle dosage group 30mg/kg, high dose group 60mg/kg.After the administration, each irritates stomach starch 5g/kg, surveys blood glucose value after 0,1,2,4,6 hour.
The influence (n=8) of table 2 pair streptozotocin rat model blood glucose
Compare with model group,
*P＜0.05,
*P＜0.01
Experimental result: rat blood sugar obviously raises after the modeling, and the sign that polydipsia, polyuria occur and become thin.After giving Fructus Corni extract and BAITANGPING, blood glucose value obviously reduces.Fructus Corni extract 30mg/kg group is better than BAITANGPING 20mg/kg group.Low dose group 15mg/kg group is more or less the same with BAITANGPING 20mg/kg group.
The specific embodiment
Describe the present invention below in conjunction with embodiment.But the present invention is not limited to given embodiment.
Embodiment 1
Fructus Corni medical material 1kg with 10 times of amount 95% alcohol heating reflux 1.5h, is extracted 2 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 95% ethanol heating for dissolving, and filtrate adds 20% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 10% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 95% ethyl alcohol recrystallization gets extract A.
HPD-100 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 50% ethanol elution, collect eluent, are concentrated into dried extractum.Extractum 95% dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 17%, and ursolic acid content is 47%, and extract B meliatin content is 22%, and morroniside content is 35%; Extract A and B get Fructus Corni extract by weight 1: 4 uniform mixing.The content of Fructus Corni extract main active of the present invention is 58.4%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=3: 8: 15: 25.Yield 2.7%.
Embodiment 2
Fructus Corni medical material 1kg with 10 times of amount 90% alcohol heating reflux 2h, is extracted 2 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid dehydrated alcohol heating for dissolving is filtered, and filtrate adds 35% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 8% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid dehydrated alcohol recrystallization gets extract A.
D101 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 40% ethanol elution, collect eluent, are concentrated into dried extractum.Extractum 96% dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 8%, and ursolic acid content is 51%, and extract B meliatin content is 21%, and morroniside content is 33%; Extract A and B get Fructus Corni extract by weight 1: 5 uniform mixing.The content of Fructus Corni extract main active of the present invention is 54.8%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=1: 7: 15: 25.Yield 2.5%.
Embodiment 3
Fructus Corni medical material 1kg with 10 times of amount 80% alcohol heating reflux 1h, is extracted 3 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 90% ethanol heating for dissolving, and filtrate adds 15% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 5% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 95% ethyl alcohol recrystallization gets extract A.
AB-8 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 55% ethanol elution, collect eluent, are concentrated into dried extractum.Extractum 97% dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 19%, and ursolic acid content is 35%, and extract B meliatin content is 22%, and morroniside content is 29%; Extract A and B get Fructus Corni extract by weight 1: 3 uniform mixing.The content of Fructus Corni extract main active of the present invention is 51.8%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=5: 10: 19: 25.Yield 3%.
Embodiment 4
Fructus Corni medical material 1kg with 12 times of amount 85% alcohol heating reflux 1h, is extracted 2 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 80% ethanol heating for dissolving, and filtrate adds 25% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 8% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 90% ethyl alcohol recrystallization gets extract A.
D101 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 80% ethanol elution, collect eluent, are concentrated into dried extractum.Extractum 100% dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 15%, and ursolic acid content is 37%, and extract B meliatin content is 24%, and morroniside content is 35%; Extract A and B get Fructus Corni extract by weight 1: 2 uniform mixing.The content of Fructus Corni extract main active of the present invention is 56.7%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=4: 12: 16: 25.Yield 2.9%.
Embodiment 5
Fructus Corni medical material 1kg with 12 times of amount 75% alcohol heating reflux 1.5h, is extracted 2 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 90% ethanol heating for dissolving, and filtrate adds 12% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 4% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 97% ethyl alcohol recrystallization gets extract A.
HPD-100 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 60% ethanol elution, collect eluent, are concentrated into dried extractum.The extractum anhydrous alcohol solution filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 8%, and ursolic acid content is 51%, and extract B meliatin content is 19%, and morroniside content is 37%; Extract A and B get Fructus Corni extract by weight 1: 4 uniform mixing.The content of Fructus Corni extract main active of the present invention is 56.6%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=1: 8: 13: 25.Yield 2.5%.
Embodiment 6
Fructus Corni medical material 1kg with 12 times of amount 70% alcohol heating reflux 1.5h, is extracted 2 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 100% ethanol heating for dissolving, and filtrate adds 20% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 7% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 80% ethyl alcohol recrystallization gets extract A.
AB-8 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 70% ethanol elution, collect eluent, are concentrated into dried extractum.Extractum 98% dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 20%, and ursolic acid content is 47%, and extract B meliatin content is 22%, and morroniside content is 36%; Extract A and B get Fructus Corni extract by weight 1: 3 uniform mixing.The content of Fructus Corni extract main active of the present invention is 60.75%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=5: 10: 15: 25.Yield 1.9%.
Embodiment 7
Fructus Corni medical material 1kg with 6 times of amount 95% alcohol heating reflux 2h, is extracted 2 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 97% ethanol heating for dissolving, and filtrate adds 15% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 6% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 85% ethyl alcohol recrystallization gets extract A.
AB-8 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 45% ethanol elution, collect eluent, are concentrated into dried extractum.Extractum 95% dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 12%, and ursolic acid content is 50%, and extract B meliatin content is 17%, and morroniside content is 36%; Extract A and B get Fructus Corni extract by weight 1: 4 uniform mixing.The content of Fructus Corni extract main active of the present invention is 54.8%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=3: 8: 12: 25.Yield 2.4%.
Embodiment 8
Fructus Corni medical material 1kg with 6 times of amount 90% alcohol heating reflux 1.5h, is extracted 3 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 95% ethanol heating for dissolving, and filtrate adds 25% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 10% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 95% ethyl alcohol recrystallization gets extract A.
D101 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 50% ethanol elution, collect eluent, are concentrated into dried extractum.Extractum 99% dissolve with ethanol filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 14%, and ursolic acid content is 53%, and extract B meliatin content is 22%, and morroniside content is 40%; Extract A and B get Fructus Corni extract by weight 1: 3 uniform mixing.The content of Fructus Corni extract main active of the present invention is 64%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=3: 10: 13: 25.Yield 2.1%.
Embodiment 9
Fructus Corni medical material 1kg with 6 times of amount 80% alcohol heating reflux 2h, is extracted 3 times.Merge extractive liquid,, being concentrated into does not have the alcohol flavor.The concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and clear liquid merge with hot water wash for isolated by filtration solid and clear liquid, solid.Solid filters with 90% ethanol heating for dissolving, and filtrate adds 20% sodium hydroxide aqueous slkali, and oil-soluble impurities is removed in filtration, and filtrate adds 10% dilute hydrochloric acid solution and transfers pH to 1～2, separates out white to yellow solid, filters, and solid 95% ethyl alcohol recrystallization gets extract A.
HPD-100 macroporous resin column on the subnatant, water and 5% ethanol flush away impurity are used 60% ethanol elution, collect eluent, are concentrated into dried extractum.The extractum anhydrous alcohol solution filters, and filtrate concentrates, and vacuum drying gets extract B.
Said extracted thing A oleanolic acid content is 18%, and ursolic acid content is 43%, and extract B meliatin content is 23%, and morroniside content is 39%; Extract A and B get Fructus Corni extract by weight 1: 3 uniform mixing.The content of Fructus Corni extract main active of the present invention is 61.8%, and wherein the effective ingredient weight ratio is an oleanolic acid: ursolic acid: meliatin: morroniside=4: 9: 15: 25.Yield 2.2%.
Claims (5)
1. Fructus Corni extract, it is characterized in that oleanolic acid in the extract, ursolic acid, the content sum of meliatin and morroniside is 40%～80%, wherein 4 kinds of weight ratio of constituentss are oleanolic acid: ursolic acid: meliatin: morroniside=1～5: 6～12: 12～20: 25.
2. Fructus Corni extract preparation technology is characterized in that comprising following steps:
The 1st step: the Fructus Corni medical material is not distinguished the flavor of to there being alcohol with the ethanol extraction of 70～95% concentration, filtering and concentrating;
The 2nd step: the concentrated solution stand at low temperature is more than 24 hours, and to neutrality, washing liquid and subnatant merge with hot water wash for isolated by filtration upper strata solid and subnatant, upper strata solid;
The 3rd step: the upper strata solid is with the ethanol heating for dissolving of 80～100% concentration, filter, filtrate adds aqueous slkali, filters and removes oil-soluble impurities, and filtrate adds acid solution and transfers pH to 1～2, separate out white to yellow solid, filter, the solid ethyl alcohol recrystallization gets extract A, wherein contain 35～55% ursolic acids in the extract A, 8～20% oleanolic acid;
The 4th step: macroporous resin column on the subnatant, water and 5% ethanol flush away impurity, with the ethanol elution of 40～80% concentration, the collection eluent is concentrated into dried extractum;
The 5th step: extractum filters with the dissolve with ethanol of 95～100% concentration, and filtrate concentrates, and vacuum drying gets extract B, wherein contains 25～40% morronisides, 15～25% meliatins in the extract B;
The 6th step: extract A and the extract B ratio uniform mixing by weight 1: 2～5 is got Fructus Corni extract.
3. Fructus Corni extract preparation technology according to claim 2 is characterized in that described: extracting method is that alcohol heating reflux extracts in the 1st step, and ethanol volume multiple is 6～12, and extraction time is 1～2 hour, and extraction time is 2～3 times.
4. according to the described Fructus Corni extract preparation technology of claim 2, it is characterized in that described: aqueous slkali is sodium hydroxide or potassium hydroxide aqueous solution in the 3rd step, and concentration is greater than 10%; Acid solution is a dilute hydrochloric acid, and concentration is less than 10%.
5. the application of the described Fructus Corni extract of claim 1 in preparation treatment diabetes and complication medicine thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100414807A CN100435810C (en) | 2005-08-15 | 2005-08-15 | Dogwood fruit extract and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100414807A CN100435810C (en) | 2005-08-15 | 2005-08-15 | Dogwood fruit extract and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733054A CN1733054A (en) | 2006-02-15 |
| CN100435810C true CN100435810C (en) | 2008-11-26 |
Family
ID=36075809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100414807A Active CN100435810C (en) | 2005-08-15 | 2005-08-15 | Dogwood fruit extract and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100435810C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103105408B (en) * | 2013-01-30 | 2016-01-06 | 河南省科高植物天然产物开发工程技术有限公司 | A kind of method differentiating Fructus Corni or spin-off |
| CN104337738A (en) * | 2014-11-14 | 2015-02-11 | 刘芳 | Composition of dogwood extracts for skin wrinkle resisting and preparation method thereof |
| CN108467416A (en) * | 2018-06-21 | 2018-08-31 | 长沙爱扬医药科技有限公司 | The method that Fructus Corni extracts morroniside, loganin and ursolic acid |
| CN109053849B (en) * | 2018-06-21 | 2021-04-16 | 长沙湘资生物科技有限公司 | Comprehensive utilization method of dogwood |
| JP7172788B2 (en) * | 2019-03-25 | 2022-11-16 | 三菱ケミカル株式会社 | Method for producing triterpenoic acid |
| CN115040558B (en) * | 2022-06-25 | 2023-05-12 | 美宝医药科技集团有限公司 | Hypoglycemic natural extract and application thereof in preparing diabetes and diabetes related metabolic syndrome products |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1424319A (en) * | 2002-12-30 | 2003-06-18 | 首都医科大学宣武医院 | Extracts of cornus officinalis and its preparation and use |
| CN1566124A (en) * | 2003-07-03 | 2005-01-19 | 和记黄埔医药企业有限公司 | Cornel extract and use thereof |
| CN1565467A (en) * | 2003-06-17 | 2005-01-19 | 成都地奥制药集团有限公司 | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine |
| CN1569119A (en) * | 2004-04-28 | 2005-01-26 | 江苏中康新药指纹图谱开发有限公司 | Dogwood extraction and its preparation method and usage |
| CN1569120A (en) * | 2004-04-28 | 2005-01-26 | 江苏中康新药指纹图谱开发有限公司 | Effective portion extraction of dogwood and its preparation method and usage |
-
2005
- 2005-08-15 CN CNB2005100414807A patent/CN100435810C/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1424319A (en) * | 2002-12-30 | 2003-06-18 | 首都医科大学宣武医院 | Extracts of cornus officinalis and its preparation and use |
| CN1565467A (en) * | 2003-06-17 | 2005-01-19 | 成都地奥制药集团有限公司 | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine |
| CN1566124A (en) * | 2003-07-03 | 2005-01-19 | 和记黄埔医药企业有限公司 | Cornel extract and use thereof |
| CN1569119A (en) * | 2004-04-28 | 2005-01-26 | 江苏中康新药指纹图谱开发有限公司 | Dogwood extraction and its preparation method and usage |
| CN1569120A (en) * | 2004-04-28 | 2005-01-26 | 江苏中康新药指纹图谱开发有限公司 | Effective portion extraction of dogwood and its preparation method and usage |
Non-Patent Citations (10)
| Title |
|---|
| 中国中医药出版社. 匡海学.中药化学. 2003 |
| 中国中医药出版社. 匡海学.中药化学. 2003 * |
| 大孔吸附树脂法分离纯化山茱萸总皂苷. 吴红.第四军医大学学报，第24卷第8期. 2003 |
| 大孔吸附树脂法分离纯化山茱萸总皂苷. 吴红.第四军医大学学报，第24卷第8期. 2003 * |
| 山茱萸总皂得提取分郭与会含量测定. 吴红.第四军医大学学报，第24卷第5期. 2003 |
| 山茱萸总皂得提取分郭与会含量测定. 吴红.第四军医大学学报，第24卷第5期. 2003 * |
| 山茱萸提取工艺的实验研究. 吴闯.江苏中医药，第25卷第2期. 2004 |
| 山茱萸提取工艺的实验研究. 吴闯.江苏中医药，第25卷第2期. 2004 * |
| 山茱萸果实有效成分提取工艺条件的选择. 薛刚.中草药，第28卷第6期. 1997 |
| 山茱萸果实有效成分提取工艺条件的选择. 薛刚.中草药，第28卷第6期. 1997 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1733054A (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101554409B (en) | Long pepper alkaloid and preparation method, preparation and application thereof | |
| CN100435810C (en) | Dogwood fruit extract and its preparation process | |
| CN102178741B (en) | Guava leaf extract with function of reducing blood sugar as well as preparation method and application thereof | |
| CN102836188B (en) | Folium microcotis total flavone extract and preparation method and application thereof | |
| CN101274012B (en) | Composition of Prunella plant extracts, preparation and pharmaceutical use thereof | |
| CN102138966A (en) | Tibetan capillaris extract and preparation method, pharmaceutical composition and use thereof | |
| CN104910240A (en) | Bougainvillea glabra triterpenoid saponin, hpyerglycemic drugs with triterpenoid saponin as active component and preparation method and application thereof | |
| CN103156869A (en) | Sanggenone C and sanggenone D extracted from morus plants and new medicine application of composition | |
| CN101332230B (en) | Prunella plant extract, and use thereof | |
| CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN103705594A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN101332229B (en) | Prunella plant extract and pharmaceutical use thereof | |
| CN101991567A (en) | Application of three biflavone monomer components extracted from ginkgo leaves in preparing medicament of alpha-glucosidase inhibitor | |
| CN102342945A (en) | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN101919901A (en) | Application of total aglycone of gleditsia sinensis and echinocystic acid in preparation of alpha-glucosidase inhibitor drugs | |
| CN103271903A (en) | Novel medical use of icaritin and cycloicaritin as well as composition thereof | |
| CN101040891B (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN100536868C (en) | Powder injection contg high content tanshin polyphenolic acid salts, and its preparation method | |
| CN104804056A (en) | Sarcopyramis nepalensis extract and application thereof | |
| CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| CN103285113B (en) | Pharmaceutical composition for preventing and/or treating diabetes mellitus | |
| CN100434091C (en) | Fenugreek seed extract and its preparing process and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210507 Address after: 215000 Building 8, No.2, South Dongwu Road, Wuzhong Economic Development Zone, Suzhou City, Jiangsu Province Patentee after: JIANGSU WUZHONG PHARMACEUTICAL Group Corp. Patentee after: JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT Co.,Ltd. Address before: 210009 10-13 / F, No.26 Majia street, Gulou District, Nanjing City, Jiangsu Province Patentee before: JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT Co.,Ltd. |